ABBOTT LABORATORIES Net Fee Amt
ABBOTT LABORATORIES (ABT) had Net Fee Amt of $1.96 million as of 2026-04-24, per its S-8 filed 2026-04-24.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-04-24
- 2026-04-24: Net Fee Amt $1.96M.
| Period end | Net Fee Amt |
|---|---|
| 2026-04-24 | $1.96M S-8 · filed 2026-04-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |